PRPH
ProPhase Labs, Inc.
Key Financials
Net Income
$-53364000
↓ 218.0%
Gross Profit
$-150000
↓ 100.9%
Operating Income
$-38629000
↓ 78.7%
Revenue
$6.8M
↓ 84.7%
Total Assets
$63.2M
↓ 31.2%
EPS (Diluted)
$-2.61
↓ 166.3%
Cash & Equivalents
$678000.00
↓ 57.9%
Shareholders' Equity
$7.4M
↓ 85.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| NT 10-Q | 5/15/2026 | View on SEC |
| NT 10-K | 3/27/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
| 8-K | 1/27/2026 | View on SEC |
| 8-K | 1/23/2026 | View on SEC |
| 8-K | 1/23/2026 | View on SEC |
| 25-NSE | 1/23/2026 | View on SEC |
| 8-K | 1/9/2026 | View on SEC |
| 8-K | 1/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PRPH |
| Company Name | ProPhase Labs, Inc. |
| CIK | 868278 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (215) 345-0919 |